Home » Topics » Nephrology, BioWorld Science

Nephrology, BioWorld Science
RSS

Positive topline data presented from phase Ib study of TAR-302 in idiopathic overactive bladder

Aug. 29, 2018

Sunitinib noninferior to nephrectomy in patients with metastatic renal-cell carcinoma

Aug. 29, 2018

Preclinical identification of a potential druggable target for chronic kidney disease

Aug. 29, 2018

Parasite protein protects mice from hemorrhagic cystitis by inducing IL-4 expression

Aug. 28, 2018

Chugai's describes candidate for the treatment of hyperphosphatemia EOS-798

Aug. 21, 2018

Adipose-derived regenerative cell therapy safe in patients with erectile dysfunction

Aug. 21, 2018

Elevated FGF23, a causative factor in the development of renal anemia and iron deficiency

Aug. 20, 2018

EC expands approval of Jinarc to include ADPKD patients with stage 4 CKD

Aug. 2, 2018

Dong-A conducts phase II study with DA-8010 in overactive bladder

July 31, 2018

Mitobridge describes new ACMSD inhibitors

July 26, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...